Are you depressed? Just relax, new FDA approved nasal spray esketamine can help you fight depression effectively.
![New Nasal Spray Can Treat Depression Much Faster New Nasal Spray Can Treat Depression Much Faster](https://images.medindia.net/health-images/1200_1000/depression-and-prejudice.jpg)
‘Are you suffering from depression? Don’t worry, a new FDA approved esketamine nasal spray can help you fight depression effectively.’
Read More..
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
The study published in the American Journal of Psychiatry is one of the key findings that led to the recent US Food and Drug Administration (FDA) approval of esketamine nasal spray, in conjunction with an oral antidepressant, for use in people with treatment-resistant depression. Read More..
![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
"This trial of esketamine was one of the pivotal trials in the FDA's review of this treatment for patients with treatment-resistant depression. Not only was adjunctive esketamine therapy effective, the improvement was evident within the first 24 hours," said Michael Thase, Professor at the University of Pennsylvania in the US.
"The novel mechanism of action of esketamine, coupled with the rapidity of benefit, underpin just how important this development is for patients with difficult to treat depression," Thase said.
The study was conducted at 39 outpatient centres from August 2015 to June 2017 and involved nearly 200 adults with moderate to severe depression and a history of not responding to at least two antidepressants.
During the research, participants were randomly assigned to one of two groups. One group was switched from their current treatment to esketamine nasal spray (56 or 84 mg twice weekly) plus a newly initiated antidepressant.
Advertisement
The improvement in depression among those in the esketamine group was significantly greater than the placebo group on day 28. Similar improvements were seen at earlier points in time, said the study.
Advertisement
The most common side effects included dissociation, nausea, vertigo, dysgeusia (distortion of the sense of taste) and dizziness. Seven percent of patients in the esketamine group discontinued the study due to the side effects.
Source-IANS